Logo image of PCSA

PROCESSA PHARMACEUTICALS INC (PCSA) Stock Fundamental Analysis

NASDAQ:PCSA - Nasdaq - US74275C3043 - Common Stock - Currency: USD

0.3247  +0.02 (+8.02%)

Premarket: 0.3294 +0 (+1.45%)

Fundamental Rating

2

Taking everything into account, PCSA scores 2 out of 10 in our fundamental rating. PCSA was compared to 195 industry peers in the Pharmaceuticals industry. While PCSA seems to be doing ok healthwise, there are quite some concerns on its profitability. PCSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PCSA had negative earnings in the past year.
In the past year PCSA has reported a negative cash flow from operations.
In the past 5 years PCSA always reported negative net income.
PCSA had a negative operating cash flow in each of the past 5 years.
PCSA Yearly Net Income VS EBIT VS OCF VS FCFPCSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of PCSA (-248.44%) is worse than 91.79% of its industry peers.
Looking at the Return On Equity, with a value of -338.53%, PCSA is doing worse than 75.90% of the companies in the same industry.
Industry RankSector Rank
ROA -248.44%
ROE -338.53%
ROIC N/A
ROA(3y)-293.95%
ROA(5y)-200.11%
ROE(3y)-431.96%
ROE(5y)-284.74%
ROIC(3y)N/A
ROIC(5y)N/A
PCSA Yearly ROA, ROE, ROICPCSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PCSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCSA Yearly Profit, Operating, Gross MarginsPCSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

PCSA has more shares outstanding than it did 1 year ago.
PCSA has more shares outstanding than it did 5 years ago.
PCSA has a worse debt/assets ratio than last year.
PCSA Yearly Shares OutstandingPCSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PCSA Yearly Total Debt VS Total AssetsPCSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -32.06, we must say that PCSA is in the distress zone and has some risk of bankruptcy.
PCSA's Altman-Z score of -32.06 is on the low side compared to the rest of the industry. PCSA is outperformed by 85.64% of its industry peers.
There is no outstanding debt for PCSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.06
ROIC/WACCN/A
WACCN/A
PCSA Yearly LT Debt VS Equity VS FCFPCSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.94 indicates that PCSA has no problem at all paying its short term obligations.
PCSA's Current ratio of 2.94 is in line compared to the rest of the industry. PCSA outperforms 50.77% of its industry peers.
PCSA has a Quick Ratio of 2.94. This indicates that PCSA is financially healthy and has no problem in meeting its short term obligations.
PCSA has a Quick ratio (2.94) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.94
Quick Ratio 2.94
PCSA Yearly Current Assets VS Current LiabilitesPCSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.48% over the past year.
EPS 1Y (TTM)50.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 61.44% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.36%
EPS Next 2Y-27.5%
EPS Next 3Y-12.29%
EPS Next 5Y61.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCSA Yearly Revenue VS EstimatesPCSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2027 2028 2029 2030 2031 100M 200M 300M
PCSA Yearly EPS VS EstimatesPCSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 -20 40 60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PCSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PCSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCSA Price Earnings VS Forward Price EarningsPCSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCSA Per share dataPCSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PCSA's earnings are expected to decrease with -12.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.5%
EPS Next 3Y-12.29%

More info and screens

0

5. Dividend

5.1 Amount

PCSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROCESSA PHARMACEUTICALS INC

NASDAQ:PCSA (6/9/2025, 8:00:00 PM)

Premarket: 0.3294 +0 (+1.45%)

0.3247

+0.02 (+8.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11
Inst Owners2.09%
Inst Owner Change72.63%
Ins Owners6.71%
Ins Owner Change11.92%
Market Cap3.86M
Analysts80
Price Target6.12 (1784.82%)
Short Float %6.24%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.47%
Min EPS beat(2)21.14%
Max EPS beat(2)61.8%
EPS beat(4)2
Avg EPS beat(4)20.23%
Min EPS beat(4)-1.04%
Max EPS beat(4)61.8%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-3.08
EYN/A
EPS(NY)-6.32
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -248.44%
ROE -338.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-293.95%
ROA(5y)-200.11%
ROE(3y)-431.96%
ROE(5y)-284.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.94
Quick Ratio 2.94
Altman-Z -32.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
EPS Next Y43.36%
EPS Next 2Y-27.5%
EPS Next 3Y-12.29%
EPS Next 5Y61.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.8%
OCF growth 3YN/A
OCF growth 5YN/A